Orbicular v. Shire-NPS: ANDA Declaratory Judgment Win on GATTEX® Teduglutide Patents
Orbicular Pharmaceutical Technologies secured a final declaratory judgment of noninfringement against Shire-NPS Pharmaceuticals over two patents protecting GATTEX® (teduglutide 5mg), clearing its ANDA path in just 87 days. Shire-NPS simultaneously waived all appeal rights, making the ruling immediately final.
ANDA challenger clears two teduglutide patents in under three months
Filed on 13 December 2024 in the Delaware District Court before Judge Joshua D. Wolson, this action was brought by Orbicular Pharmaceutical Technologies Pvt. Ltd. seeking declaratory judgment that its proposed ANDA product does not infringe US7847061B2 or US9060992B2, both held by Shire-NPS Pharmaceuticals, Inc. and covering GATTEX®, an injectable recombinant teduglutide product used in the treatment of short bowel syndrome.
The case closed on 10 March 2025 — just 87 days after filing — with the Court entering final judgment in Orbicular’s favour on both patents. The declaratory judgment covers manufacture, use, sale, offer to sell, marketing, and importation of Orbicular’s ANDA product, and explicitly extends to all extensions, reissues, reexaminations, and associated exclusivities. Crucially, Shire-NPS waived any right to appeal, and each party was ordered to bear its own costs.
The 87-day resolution is notably short for Hatch-Waxman ANDA litigation, which typically extends for years. The consent to judgment and appeal waiver by Shire-NPS suggests the parties reached a negotiated resolution — possibly a litigation settlement or commercial agreement — though the public record discloses no licensing terms. The absence of fee-shifting implies neither party sought to characterise the litigation as exceptional under 35 U.S.C. § 285.
Filing to Judgment on the merits for Plaintiff in 87 days
87 days — well below the median ANDA patent case duration, suggesting early consent or agreement
Final declaratory judgment of noninfringement: what the ruling means for both parties
Declaratory judgment clears both ANDA patents in one ruling
A declaratory judgment of noninfringement is a court’s affirmative finding that the challenger’s proposed product does not infringe the asserted patents — either literally or under the doctrine of equivalents. Here, the Court entered final judgment covering both US7847061B2 and US9060992B2 simultaneously, encompassing all current and future extensions and exclusivities. This provides Orbicular with a single, comprehensive clearance document for its ANDA filing.
Hatch-Waxman DJ actionOrbicular secures full patent clearance for its teduglutide ANDA product
Orbicular obtains an immediately enforceable, non-appealable declaration that its ANDA product does not and will not infringe either patent. Because Shire-NPS expressly waived appeal rights, the judgment is final in every practical sense. This removes the last patent barrier to FDA approval and commercial launch, assuming no other listed patents remain. The ruling covers all forms of commercial activity: manufacture, use, sale, offer to sell, marketing, and importation.
Non-appealable clearance grantedShire-NPS waives appeal, ending exclusivity defence on these two patents
By consenting to judgment and waiving appeal rights, Shire-NPS accepted that these two patents will no longer block Orbicular’s ANDA. This is consistent with a negotiated resolution — potentially involving a settlement or agreed launch date — though no commercial terms are disclosed in the public record. The ruling does not speak to any remaining Orange Book patents, formulation patents, or method-of-treatment claims that may still be listed for GATTEX®.
Appeal rights waived by consentGeneric teduglutide entry path opens; broader patent landscape remains a variable
This judgment signals that at least two core teduglutide patents are no longer enforceable against Orbicular’s specific ANDA product, opening a credible generic entry pathway. Other ANDA filers in the teduglutide space should note the precedent, though noninfringement findings are product-specific and do not automatically bind third-party challengers. Companies operating in the GLP-2 analogue or injectable biopharmaceutical space should monitor the Orange Book listing for GATTEX® for any remaining patent assertions.
Generic entry pathway clearedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Orbicular Pharmaceutical Technologies Pvt., Ltd. | Company | Indian generic pharmaceutical developer — holder of ANDA seeking to market teduglutide injectable productSearch in Eureka ↗ |
| Defendant | Shire-NPS Pharmaceuticals, Inc. | Company | Shire-NPS Pharmaceuticals, Inc. — holder of GATTEX® (teduglutide) patents US7847061B2 and US9060992B2Search in Eureka ↗ |
| Plaintiff counsel | Ajay Kayal | Attorney | Counsel for Orbicular Pharmaceutical Technologies Pvt., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Cortlan S. Hitch | Attorney | Counsel for Orbicular Pharmaceutical Technologies Pvt., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Joanna G. Goldstein | Attorney | Counsel for Orbicular Pharmaceutical Technologies Pvt., Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Kenneth Laurence Dorsney | Attorney | Counsel for Orbicular Pharmaceutical Technologies Pvt., Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Morris James LLP | Law Firm | Representing Orbicular Pharmaceutical Technologies Pvt., Ltd.Search in Eureka ↗ |
| Defendant counsel | Derek James Fahnestock | Attorney | Counsel for Shire-NPS Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Karen Jacobs | Attorney | Counsel for Shire-NPS Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Shire-NPS Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Joshua D. Wolson | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The judgment’s language is deliberately comprehensive — covering not only direct infringement but also induced and contributory infringement, and extending explicitly to ‘all extensions, reissues, reexaminations, renewals, extensions and associated exclusivities.’ This breadth is characteristic of a negotiated consent order rather than a litigated verdict, suggesting Shire-NPS agreed to the scope. The express appeal waiver in paragraph 6 is a significant procedural concession that transforms this district court ruling into a final, binding clearance with no further litigation pathway on these two patents.
US7847061B2 & US9060992B2 — Teduglutide Recombinant Formulations for GATTEX®
US7847061B2 (application no. 11/262980) and US9060992B2 (application no. 12/938117) both relate to teduglutide, a recombinant analogue of glucagon-like peptide-2 (GLP-2) used in GATTEX® for the treatment of short bowel syndrome. These patents cover the composition and pharmaceutical formulation of the 5mg single-use injectable vial product. Teduglutide is a biologically derived peptide, placing these patents at the intersection of recombinant biologics and specialty pharmaceutical formulation.
From a competitive standpoint, Orange Book-listed patents on branded injectable biologics like GATTEX® function as market exclusivity tools under Hatch-Waxman. A noninfringement finding against these two patents represents a significant erosion of Shire-NPS’s (now Takeda’s) patent barrier against generic teduglutide entry. Companies developing GLP-2 analogues or pursuing teduglutide biosimilar or ANDA programmes should map the full continuation and divisional landscape stemming from these application numbers to assess residual risk.
Should you run an FTO against US7847061B2 and US9060992B2?
Any pharmaceutical company developing a teduglutide injectable product — whether as an ANDA generic, a 505(b)(2) product, or a related GLP-2 analogue — should conduct a freedom-to-operate analysis against both patents and their continuation families. Although Orbicular has obtained a product-specific noninfringement finding, that ruling does not extend to other developers’ formulations. The scope of claims in US7847061B2 and US9060992B2 may still read on different teduglutide compositions or manufacturing processes.
PatSnap Eureka’s FTO Search Agent enables R&D and IP teams to map the full claim scope of both patents, identify related family members and continuations, and cross-reference against your specific product formulation and process. The tool flags active claims, expired claims, and any inter partes review history that may affect enforceability — giving product teams a defensible FTO position before entering the teduglutide market.
Run a freedom-to-operate analysis on US9060992B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA Declaratory Judgment Cases Involving Injectable Biopharmaceutical Patents
Explore comparable Hatch-Waxman ANDA noninfringement actions filed in Delaware District Court involving recombinant peptide and injectable biopharmaceutical patents.
What this case signals for the injectable biopharmaceutical ANDA IP landscape
A consent-based DJ judgment resolved in 87 days carries distinct signals for generic entrants and branded biologics holders in the Hatch-Waxman space.
Consent judgments with appeal waivers create non-challengeable clearance
When a branded patentee agrees to a noninfringement judgment and expressly waives appeal, the generic challenger obtains the strongest possible patent clearance — one that cannot be undone on appeal. Generic filers and their investors should specifically seek this structure in settlement negotiations.
87-day resolution suggests negotiated terms beyond the public docket
Hatch-Waxman cases rarely resolve in under 90 days without a commercial agreement underpinning the legal outcome. The absence of fee-shifting and the mutual ‘own costs’ order are consistent with a structured settlement. Practitioners monitoring this space should request SEC disclosures from publicly listed counterparties for commercial terms.
Orbicular v Shire-NPS — key questions answered
The Delaware District Court entered a final declaratory judgment of noninfringement in favour of Orbicular on both US7847061B2 and US9060992B2. The judgment covers all commercial activities related to Orbicular’s ANDA product and extends to all patent extensions and exclusivities. Shire-NPS waived all appeal rights, and each party bears its own costs.
Two Orange Book-listed patents were at issue: US7847061B2 (application 11/262980) and US9060992B2 (application 12/938117), both relating to teduglutide recombinant formulations covering GATTEX®, a 5mg injectable product used for short bowel syndrome and marketed by Shire-NPS (Takeda).
No. Declaratory judgments of noninfringement are product- and party-specific under U.S. patent law. Other ANDA applicants cannot rely on this ruling as collateral estoppel against the same patents. Each separate ANDA filer must independently establish noninfringement or invalidity of US7847061B2 and US9060992B2 for their specific product formulation.
The 87-day resolution is substantially faster than typical Hatch-Waxman litigation. The consent judgment structure and Shire-NPS’s express waiver of appeal rights strongly suggest the parties reached a negotiated commercial agreement underpinning the legal outcome. However, no settlement terms or licensing arrangements are disclosed in the public case record.
Shire-NPS’s appeal waiver means the noninfringement judgment on both patents is immediately final and cannot be challenged in the Federal Circuit. This removes appellate uncertainty from Orbicular’s commercialisation timeline for these two patents. However, Orbicular must still obtain FDA approval for its ANDA and clear any other listed patents or regulatory exclusivities that may apply to GATTEX® NDA 203441.
PatSnap Eureka searches patents and litigation data to answer instantly.